Aurinia Pharmaceuticals Inc. AUPH
Set alert
16.65 USD -0.56 -3.25%
At close
16.65 0.00 0.00%
Pre-market · Nov 2, 8:03 AM ET
16.48 Day range 17.04
12.79 52-week range 19.25
- YTD
- +4.39%
- 1 year
- +37.38%
- Open
- 16.76
- Prev close
- 17.21
- Mkt cap
- 2.23B
- Vol
- 960.84K
- Avg vol
- 914.71K
- EPS
- 2.28
- P/E
- 7.30
- Div yield
- 0.00%
More statistics
- Low
- 16.48
- High
- 17.04
- Forward P/E
- 14.26
- Beta
- 1.61
- Short ratio
- 8.95
- Inst. own
- 60.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 25, 2027
- 50-d avg
- 16.50
- 200-d avg
- 15.64
- 1y target
- 18.00
5Y chart
Events in this range
- Aug 1, 2025Rating: RBC Capital · Outperform → Outperform
- Nov 4, 2025Earnings: 0.23; estimate 0.16; surprise 43.75%
- Nov 5, 2025Downgrade: RBC Capital · Outperform → Sector Perform
- Nov 7, 2025Rating: Jefferies · Hold → Buy
- Dec 3, 2025Downgrade: Leerink Partners · Outperform → Market Perform
- Feb 26, 2026Earnings: 0.26; estimate 0.21; surprise 23.81%
- May 7, 2026Earnings: 0.25; estimate 0.18; surprise 38.89%
- Aug 6, 2026Earnings: 0.28; estimate 0.24; surprise 16.67%
- Aug 7, 2026Rating: RBC Capital · Sector Perform → Sector Perform
- Oct 21, 2026Rating: TD Cowen · Buy → Buy
- Oct 30, 2026Earnings: 0.23; estimate 0.22; surprise 4.55%
Signals (90)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Oct 30, 2026 | 2 days ago |
| MACD: Buy Signal | Oct 19, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 28, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 3 months ago |
| SMA: Bearish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 20, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 6, 2026 | 3 months ago |
| SMA: Bearish | Jun 29, 2026 | 4 months ago |
| RSI: Overbought | Jun 22, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 1, 2026 | 5 months ago |
| SMA: Bearish | May 18, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 27, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bullish | Mar 23, 2026 | 7 months ago |
| SMA: Bearish | Mar 9, 2026 | 7 months ago |
| MACD: Sell Signal | Jan 5, 2026 | 10 months ago |
| SMA: Bearish | Dec 29, 2025 | 10 months ago |
| RSI: Overbought | Nov 3, 2025 | 12 months ago |
| SMA: Bullish | Oct 27, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 27, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Sep 29, 2025 | 1 year ago |
| RSI: Overbought | Aug 4, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| SMA: Bullish | Jul 7, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 7, 2025 | 1 year ago |
| SMA: Bearish | Jun 30, 2025 | 1 year ago |
| SMA: Bearish | Jun 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 30, 2025 | 1 year ago |
| SMA: Bullish | Jun 23, 2025 | 1 year ago |
| SMA: Bullish | Jun 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 23, 2025 | 1 year ago |
| SMA: Bearish | Jun 16, 2025 | 1 year ago |
| SMA: Bullish | Jun 2, 2025 | 1 year ago |
| SMA: Bearish | May 26, 2025 | 1 year ago |
| SMA: Bullish | May 12, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| SMA: Bearish | May 5, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| SMA: Bullish | Apr 21, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Mar 31, 2025 | 1 year ago |
| SMA: Bullish | Mar 3, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 13, 2025 | 1 year ago |
| SMA: Bearish | Dec 30, 2024 | 1 year ago |
| RSI: Overbought | Nov 18, 2024 | 1 year ago |
| RSI: Overbought | Nov 4, 2024 | 1 year ago |
| SMA: Bullish | Oct 28, 2024 | 2 years ago |
| SMA: Bearish | Oct 21, 2024 | 2 years ago |
| SMA: Bullish | Aug 12, 2024 | 2 years ago |
| SMA: Bullish | Aug 12, 2024 | 2 years ago |
| SMA: Bearish | Jul 29, 2024 | 2 years ago |
| SMA: Bullish | May 13, 2024 | 2 years ago |
| MACD: Buy Signal | May 13, 2024 | 2 years ago |
| RSI: Oversold | Mar 18, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 15, 2024 | 2 years ago |
| SMA: Bearish | Jan 1, 2024 | 2 years ago |
| SMA: Bearish | Dec 25, 2023 | 2 years ago |
| SMA: Bullish | Dec 11, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 20, 2023 | 2 years ago |
| SMA: Bullish | Nov 13, 2023 | 2 years ago |
| SMA: Bearish | Nov 6, 2023 | 2 years ago |
| SMA: Bullish | Oct 30, 2023 | 3 years ago |
| SMA: Bearish | Jul 31, 2023 | 3 years ago |
| SMA: Bearish | Jul 31, 2023 | 3 years ago |
| MACD: Sell Signal | Jul 31, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 24, 2023 | 3 years ago |
| SMA: Bullish | Jul 3, 2023 | 3 years ago |
| MACD: Sell Signal | May 29, 2023 | 3 years ago |
| SMA: Bearish | May 15, 2023 | 3 years ago |
| SMA: Bullish | Jan 2, 2023 | 3 years ago |
| SMA: Bullish | Jan 2, 2023 | 3 years ago |
| SMA: Bearish | Oct 31, 2022 | 4 years ago |
| RSI: Oversold | Oct 31, 2022 | 4 years ago |
| SMA: Bullish | Oct 24, 2022 | 4 years ago |
| RSI: Oversold | Jul 25, 2022 | 4 years ago |
| SMA: Bearish | Jul 11, 2022 | 4 years ago |
| SMA: Bullish | Jun 20, 2022 | 4 years ago |
| SMA: Bearish | Jun 13, 2022 | 4 years ago |
| RSI: Oversold | Jun 13, 2022 | 4 years ago |
| SMA: Bullish | Jun 6, 2022 | 4 years ago |
| SMA: Bearish | May 30, 2022 | 4 years ago |
| RSI: Oversold | May 30, 2022 | 4 years ago |
| SMA: Bullish | May 16, 2022 | 4 years ago |
Key statistics
- Market cap
- 2.22B
- Enterprise value
- 1.91B
- Trailing P/E
- 7.30
- Forward P/E
- 14.26
- PEG ratio
- 0.00
- Price / sales
- 7.11
- Price / book
- 3.60
- EPS (TTM)
- 2.28
- Beta
- 1.61
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 100.84%
- Revenue (TTM)
- 311.51M
- Revenue growth
- 18.90%
- Free cash flow
- 147.82M
- Total cash
- 443.02M
- Total debt
- 64.14M
- Return on equity
- 66.12%
- Shares outstanding
- 133.05M
- Short % of float
- 6.46%
- 50-day average
- 16.50
- 200-day average
- 15.64
Analyst view
Consensus: buy
Buy
Price target (mean) 18.00 +8.1% upside
Now 16.65
- Target (low)
- 16.00
- Target (mean)
- 18.00
- Target (high)
- 21.00
Ratings (0m) 7 5 buy · 2 hold · 0 sell
- Strong buy0
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 0.22.
Financials — quick view
AUPH Revenue — quarterly 83.70M
AUPH Net income — quarterly 31.70M
AUPH EPS — quarterly 0.24
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 0.19 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | 0.22 | 0.23 | +0.01 | +4.55% |
| Aug 6, 2026 | Jun 30, 2026 | 0.24 | 0.28 | +0.04 | +16.67% |
| May 7, 2026 | Mar 31, 2026 | 0.18 | 0.25 | +0.07 | +38.89% |
| Feb 26, 2026 | Dec 31, 2025 | 0.21 | 0.26 | +0.05 | +23.81% |
| Nov 4, 2025 | Sep 30, 2025 | 0.16 | 0.23 | +0.07 | +43.75% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 21, 2026 | TD Cowen | main | Buy | Buy |
| Aug 7, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Dec 3, 2025 | Leerink Partners | down | Outperform | Market Perform |
| Nov 7, 2025 | Jefferies | up | Hold | Buy |
| Nov 5, 2025 | RBC Capital | down | Outperform | Sector Perform |
| Aug 1, 2025 | RBC Capital | main | Outperform | Outperform |
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- auriniapharma.com
News
- Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
- Aurinia Pharmaceuticals Raises FY2026 Sales Guidance from $315.000M-$325.000M to $325.000M-$330.000M vs $330.261M Est
- Aurinia Pharmaceuticals Q3 EPS $0.23 Beats $0.22 Estimate, Sales $83.699M Beat $83.691M Estimate
- Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
- Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
- Why Aurinia Pharmaceuticals (AUPH) is a Top Growth Stock for the Long-Term
- TD Cowen Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $18
- Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
- Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037
- RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $16
Your note
Sign in to keep a note on AUPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Aurinia Pharmaceuticals | Issuer | Redemption, retraction, cancelation, repurchase | May 7, 2026 | 56,531 |
| Bailey (Jeffrey Allen) | Director of Issuer | Exercise of rights | Nov 20, 2025 | 22,775 |
| Donley (Matthew Maxwell) | Senior Officer of Issuer | Exercise of rights | Mar 1, 2026 | 440,053 |
| Greenleaf (Peter S) | Director of Issuer | Exercise of rights | Mar 1, 2026 | 1,050,043 |
| Johnson (Craig A) | Director of Issuer | Exercise of rights | Nov 20, 2025 | 14,592 |
| Keenan (Gregory M.D.) | Senior Officer of Issuer | Exercise of rights | Mar 5, 2026 | 28,532 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Tang Capital Management, LLC | 9.80% | 13,044,106 | 217.18M | Jun 29, 2026 |
| Blackrock Inc. | 6.16% | 8,193,085 | 136.41M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 4.22% | 5,619,401 | 93.56M | Jun 29, 2026 |
| NEA Management Company, LLC | 2.98% | 3,969,834 | 66.10M | Jun 29, 2026 |
| Two Sigma Investments, LP | 2.61% | 3,467,514 | 57.73M | Jun 29, 2026 |
| Arrowstreet Capital, Limited Partnership | 2.45% | 3,264,062 | 54.35M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Russell 2000 ETF | 2.32% | 3,089,770 | 51.44M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.98% | 1,303,109 | 21.70M | Jul 30, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.84% | 1,116,707 | 18.59M | Sep 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.69% | 917,683 | 15.28M | Sep 29, 2026 |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 0.46% | 613,258 | 10.21M | May 30, 2026 |
| Goldman Sachs Trust-Goldman Sachs U.S. Tax-Managed Equity Fund | 0.41% | 541,443 | 9.02M | Jun 29, 2026 |